Spatial transcriptomics maps early B-cell and T-cell activation in hidradenitis suppurativa

Further Publications Dermatology

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

J Eur Acad Dermatol Venereol

Onfroy A, Jean-Louis F, Le Corvoisier P, Coulpier F, Muret K, Bonnet E, Arrouasse R, Boucle C, Abid S, Sbidian E, Bergqvist C, Wolkenstein P, Godot V, Deleuze JF, Lévy Y, Topilko P, Audureau E, Hue S

doi: 10.1111/jdv.70152

Systemic Lupus Erythematosus

CD72 downregulation on DN2 B cells associates with disease activity and resistance to rituximab in systemic lupus erythematosus

Rheumatology (Oxford)

Wangriatisak K, Huang W, Sechi G, Oke V, Chemin K, Grönwall C, Gunnarsson I, Malmström V, Faustini F

doi: 10.1093/rheumatology/keag097

T Cells

BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy

J Clin Immunol

Mora-Buch R, Tomás-Marín M, Pasamar H, Enrich E, Peña-Gómez C, Rudilla F

doi: 10.1007/s10875-025-01901-2

Melanoma and Skin Cancer

Spatial Proteomics of Tertiary Lymphoid Structures Reveals Correlation with Immunotherapy Response in Merkel Cell Carcinoma

Br J Dermatol

Nakamura M, Ogata D, Kato J, Ko YW, Hu J, Yoshimitsu M, Magara T, Kano S, Nakamura R, Kato H, Maekawa T, Yasuda M, Kiniwa Y, Ishikawa H, Nakamura Y, Nagase K, Morita A

doi: 10.1093/bjd/ljaf525

T CellsFurther Publications Dermatology

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity

Nature

Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM, Kilian M, Fehrenbacher L, Pernin F, Rone JM, Lee HG, Piester G, Kenison JE, Lee JH, Illouz T, Polonio CM, Srun L, Martinez J, Chung EN, Schüle A, Plasencia A, Li L, Ferrara K, Lewandrowski M, Strathdee CA, Lerner L, Quéva C, Clark IC, Deneen B, Lieberman J, Sherr DH, Antel JP, Wheeler MA, Ligon KL, Chiocca EA, Prinz M, Reardon DA, Quintana FJ

doi: 10.1038/s41586-025-08997-x

Psoriasis

Unrestrained MyD88 signaling in A20-deficient keratinocytes triggers T cell dependent Psoriatic Arthritis like disease

J Invest Dermatol

Tobias R, Kumar S, Liu J, Lenci N, Gharabi A, Stibor D, Advincula R, Achacoso P, Huang ZM, Bowman C, Ricardo-Gonzalez R, Nakamura MC, Liao W, Malynn BA, Ma A, Razani B

doi: 10.1016/j.jid.2025.03.043

Acne

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

J Eur Acad Dermatol Venereol

Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC

doi: 10.1111/jdv.70356

Atopic Dermatitis

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

J Eur Acad Dermatol Venereol

Nikolakis G, Alpsoy E, Anzengruber F, Augustin M, Bechara FG, Becherel PA, Benhadou F, Bettoli V, Cabete J, Caposiena Caro RD, Di Cesare A, Damiani G, Dini V, Giamarellos-Bourboulis EJ, Gáspár K, Glasenhardt K, Guillem P, Hafner A, Horvath B, Ingram JR, Jarienè V, Jemec GBE, Katoulis A, Kirsten N, Kokolakis G, Krajewski PK, Liakou AI, Manzo Margiotta F, Marzano AV, Martorell A, Matusiak L, Mintoff D, Molina Leyva A, Pinter A, Pirogova A, Podda M, Prignano F, Romani J, Romanelli M, Rosi E, Sahin S, Saunte DML, Schneider-Burrus S, Suppa M, Szepietowski J, Szegedi A, Thomsen SF, Tzellos T, Trigoni A, Van Der Zee HH, Van Straalen K, Valiukevičiene S, Vilarrasa E, von Stebut E, Zouboulis CC

doi: 10.1111/jdv.70264

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Related content

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

CD72 downregulation on DN2 B cells associates with disease activity and resistance to rituximab in systemic lupus erythematosus

BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy

Spatial Proteomics of Tertiary Lymphoid Structures Reveals Correlation with Immunotherapy Response in Merkel Cell Carcinoma

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity

Unrestrained MyD88 signaling in A20-deficient keratinocytes triggers T cell dependent Psoriatic Arthritis like disease

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension